Condition: Glioblastoma · Sponsor: SignPath Pharma, Inc.
The objective of this study is to assess the tolerability, safety, and efficacy of Liposomal Curcumin (LC) in combination with radiotherapy (RT) and Temozolomide (TMZ) in patients with newly diagnosed High-Grade Gliomas (HGG).
This description comes directly from the study's public registry record.
Michaella Lacoboni, RN, BSN · 410-955-4009 · Msheeh13@jh.edu
Michelle Comas · 801-557-1214 · mcomas@signpathpharma.com
Always discuss trial participation with your own doctor first.
| Sibley Memorial Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| Johns Hopkins University/Johns Hopkins Hospital | Baltimore, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05768919